Skip to main content

Cancer Research

Roswell Park Cancer Institute Collaboration with CHS

Bhoomi Mehrotra, MD and Mitchell Chorost, MD

Image
bhoomi mehrotra with patient

Catholic Health Systems (CHS) has strengthened its commitment to providing outstanding cancer care for Long Islanders by becoming a member of the newly launched Roswell Park Care Network. One of New York’s premier cancer centers, Roswell Park is nationally recognized as a leader in this field of medicine. In a highly selective process, the Buffalo-based comprehensive cancer center is now partnering with CHS to expand its research network into the downstate region. This agreement provides a collaboration between CHS and Roswell Park for research participation in Roswell Park’s proprietary clinical trials as well those associated with the NCI cooperative research group, Alliance for Clinical Trials in Oncology.

“The field of oncology has made major strides in the past three to five years, based upon novel research. All of those advances have happened by individuals participating in clinical trials,” commented CHS’s Chair of Oncology Bhoomi Mehrotra, MD. “Our partnership with Roswell will give cancer patients in our region access to those innovations.”

“Having completed my surgical oncology fellowship at Roswell Park, I can attest to the expertise of their oncology researchers and their commitment to cancer patients to provide optimal care. The research staff of St Francis Hospital is looking forward to building upon this relationship and providing opportunities for participation in a clinical trials for our patients. Through research, we hope to improve the care that we deliver” stated Mitchell Chorost, MD, Chairman of St. Francis Hospital's IRB.

In this exclusive partnership for the region, CHS and Roswell Park are launching what is expected to be an exciting collaboration. The new clinical trials will initially be conducted at St. Francis, augmenting currently available studies and innovative therapies offered to Long Islanders. Eventually, these programs will be implemented across the health system, helping to ease the burden of cancer for communities in Nassau, Suffolk and beyond.

Current Open Clinical Trials

Breast Cancer

  • Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • A Randomized Phase III Double Blinded Placebo Controlled Trial of Asprin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
  • A phase lll Double-blind randomized study assessing the efficacy of capivasertib + paclitaxel versus placebo + paclitaxel as first-line treatment for patients with histologically confirmed locally advanced or metastatic triple-negative breast cancer (TNBC)

Chronic Lymphocytic Leukemia

  • Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia

Colon Cancer

  • Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch

Leukemia

  • A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients with AML Harboring Mutations in IDH2 who have Failed or been Refractory to Frontline Treatment

Metastatic Disease

  • ASTEROID- Assessing Single-Fraction SBRT versus Standard Palliative Radiation in Patients with Metastatic Disease

Multiple Myeloma

What is multiple myeloma?

Watch: Signs and Symptoms of Myeloma (Courtesy of Roswell Park Comprehensive Care Center)

  • Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept to Overcome Resistance to Chemotherapy
    • Principal Investigator: Dr. Dilip Patel
    • Summary: This Phase II trial studies how well abatacept, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that is resistant to chemotherapy. Abatacept may block certain proteins that are present on multiple myeloma cells that have been shown to protect against chemotherapy. Drugs used in chemotherapy, such as ixazomib citrate and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abatacept, ixazomib citrate, and dexamethasone may work better at treating patients with multiple myeloma resistant to chemotherapy.
    • Read more about the study
  • (LocoMMotion Study): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment

Other

  • Cadence Registry Sanofi CADENCE Registry - Cold Agglutinin Disease Real World Evidence Registry 
    • Principal Investigator: Dr. George Zervos
  • Advanced Cardiac Imaging in Detection of Cardiotoxicity of Cancer Chemotherapy
    • Principal Investigator: Dr. Nathaniel Reichek
  • St. Francis Hospital Cardio-Oncology Registry 
    • Principal Investigator: Dr. Haoyi Zheng
  • The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
    • Principal Investigator: Dr. Dilip Patel
Share